Abstract
The CC Chemokine Receptor 1 (CCR1) is closely related to various chronic inflammatory diseases like rheumatoid arthritis and multiple sclerosis, and plays a crucial role in transplant rejection. Inhibiting its activity with CCR1 antagonists has been proved to be effective in preventing some diseases. A number of in vivo experiments have been carried out to shed light on the underlying mechanism of the interactions between the CCR1 and its ligands. However, their conclusions are still controversial. In this study, ligand-based computational drug design is applied as a new and effective way to study the structure-activity relationship of CCR1 antagonists. Three-dimensional pharmacophore models were generated for CCR1 antagonists, using both HypoGen and HipHop algorithms in Catalyst software. Two optimal pharmacophore models were defined through careful qualification processes. Both of them have four features: one hydrogen-bond acceptor, one positive ionable and two hydrophobic groups. Additional information was obtained through comparison between the two models. Our results can be valuable tools for the discovery and development of specific, highly potent CCR1 antagonists. For Supplement material, please see the online version of the article. For Supplement material, please see the online version of the article.
Keywords: Chemokine, CC chemokine receptor 1 antagonist, pharmacophore model
Medicinal Chemistry
Title: 3D-Pharmacophere Models for CC Chemokine Receptor 1 Antagonists
Volume: 5 Issue: 4
Author(s): Yixi Liu, Philippe Andre, Jing Wei and Kang Zhao
Affiliation:
Keywords: Chemokine, CC chemokine receptor 1 antagonist, pharmacophore model
Abstract: The CC Chemokine Receptor 1 (CCR1) is closely related to various chronic inflammatory diseases like rheumatoid arthritis and multiple sclerosis, and plays a crucial role in transplant rejection. Inhibiting its activity with CCR1 antagonists has been proved to be effective in preventing some diseases. A number of in vivo experiments have been carried out to shed light on the underlying mechanism of the interactions between the CCR1 and its ligands. However, their conclusions are still controversial. In this study, ligand-based computational drug design is applied as a new and effective way to study the structure-activity relationship of CCR1 antagonists. Three-dimensional pharmacophore models were generated for CCR1 antagonists, using both HypoGen and HipHop algorithms in Catalyst software. Two optimal pharmacophore models were defined through careful qualification processes. Both of them have four features: one hydrogen-bond acceptor, one positive ionable and two hydrophobic groups. Additional information was obtained through comparison between the two models. Our results can be valuable tools for the discovery and development of specific, highly potent CCR1 antagonists. For Supplement material, please see the online version of the article. For Supplement material, please see the online version of the article.
Export Options
About this article
Cite this article as:
Liu Yixi, Andre Philippe, Wei Jing and Zhao Kang, 3D-Pharmacophere Models for CC Chemokine Receptor 1 Antagonists, Medicinal Chemistry 2009; 5(4) . https://dx.doi.org/10.2174/157340609788681502
DOI https://dx.doi.org/10.2174/157340609788681502 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
MiRNAs in Bone Diseases
MicroRNA Comparison of Two Molecular Scaffolds, 5-Methylisoxazole-3-Carboxamide and 5-Methylisoxazole-4-Carboxamide
Current Pharmaceutical Design Cellular and Molecular Mechanisms Involved in the Action of Vitamin D Analogs Targeting Vitiligo Depigmentation
Current Drug Targets Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology Molecular Docking Study for Analyzing the Inhibitory Effect of Anti-inflammatory Plant Compound Against Tumour Necrosis Factor (TNF-α)
Current Drug Therapy The Role of Cytokines in Sleep Regulation
Current Pharmaceutical Design Molecular Interaction Study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 Kinase and JNK Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry De-Risking Bio-therapeutics for Possible Drug Interactions Using Cryopreserved Human Hepatocytes
Current Drug Metabolism Tyrosine Hydroxylase Gene: Another Piece of the Genetic Puzzle of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Bioactive Fish Fatty Acids: Health Effects and Their Use as Functional Food Ingredients
Current Nutrition & Food Science COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management
Current Topics in Medicinal Chemistry Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Current Drug Delivery Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry Modulation of Photosensitization Processes for an Improved Targeted Photodynamic Therapy
Current Medicinal Chemistry Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy
Current Pharmaceutical Biotechnology Genetic Susceptibility to Autoimmune Disorders: Clues from Gene Association and Gene Expression Studies
Current Molecular Medicine Interleukin-26, An Epitheliotropic T-Cell Cytokine
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Human Interleukin-19: Structure, Function and Disease Associations
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry